Apollomics Announces Approval Of Vebreltinib In China As A First-In-Class Treatment For Gliomas With MET Fusion Gene
Portfolio Pulse from Benzinga Newsdesk
Apollomics Inc. announced that its partner Avistone received approval from China's NMPA for vebreltinib as a treatment for gliomas with MET fusion gene. This marks vebreltinib as the first c-Met inhibitor approved for CNS tumors with c-Met alteration. The approval is based on the positive results of the FUGEN study, showing significant improvement in median overall survival for patients with ZM fusion-positive glioma. Apollomics retains rights outside China, with ongoing global studies showing similar promising results.
April 25, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Apollomics Inc. receives significant regulatory approval in China for vebreltinib, a treatment for gliomas with MET fusion gene, through its partner Avistone. This approval could enhance Apollomics' global positioning in oncology, especially for CNS tumors.
The approval of vebreltinib in China represents a significant milestone for Apollomics, potentially boosting its stock due to the expansion of its treatment portfolio into new, difficult-to-treat cancers. The positive results from the FUGEN study and ongoing global trials could signal strong future revenues and enhance investor confidence in the company's research and development capabilities.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100